View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 3, 2022

LumiraDx obtains CE mark for NT-proBNP test for congestive heart failure

The LumiraDx NT-proBNP test will measure the NT-proBNP levels in human capillary, venous whole blood and plasma samples.

LumiraDx has obtained CE mark for its new NT-proBNP test, a rapid and easy to use microfluidic immunofluorescence assay, which is used for diagnosing congestive heart failure (CHF).

The device has been designed for measuring the NT-proBNP levels in human capillary, venous whole blood and plasma samples.

It provides results in 12 minutes from sample application and helps in monitoring the peptide levels that are raised during many majority forms of heart failure.

The direct fingerstick assay is intended to be used in community-based healthcare settings for accurately and rapidly diagnosing individuals who are suspected of having CHF.

Additionally, the company obtained an updated CE mark for its D-Dimer test which will now include detection of venous thromboembolism (VTE) in symptomatic patients.

The LumiraDx D-Dimer Test is a fluorescence immunoassay which has been designed for measuring D-Dimer levels in human whole blood and plasma at a point of care (POC) setting.

The expanded CE marking will now allow the test to be used, together with a clinical pre-test probability assessment model, for detecting VTE in symptomatic patients.

LumiraDx stated that a prospective clinical trial (EMBOL) was conducted in the UK and Germany, in 618 symptomatic patients.

Findings showed that the LumiraDx D-Dimer test has strong correlation with the laboratory reference method, with 99.5% negative predictive value at the 500ug/L cut off, when used together with a pretest probability score.

LumiraDx CEO Ron Zwanziger said: “The new and updated CE Marks for our NT-proBNP and D-Dimer tests represent an important advancement in cardiovascular testing in the point of care space.

“Our new tests deliver results in minutes from an easy-to-collect fingerstick sample, allowing fast and accurate management of cardiovascular conditions by first responders, primary care, urgent care, and the emergency department.

“Being able to do this at the point of care can improve patient pathways, reduce strains on health systems, specifically emergency departments and lead to improved patient outcomes.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network